Real‐world effectiveness of monoclonal antibody inhibitors of <scp>PCSK</scp>9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study
In a real-world cohort of HeFH patients, most of which were intolerant to statins, a high majority were able to achieve a ≥50% reduction in LDL-C after 12 months of PCSK9 inhibitor therapy (mean reduction of approximately 59%), which is similar to clinical trial data of patients with ASCVD. A significant reduction in non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) were also observed.
Authors
- Susan Buchkowsky
- Arden R. Barry (ORCID: https://orcid.org/0000-0002-0287-898X)
- Mark Pryjma
- Rebecca Siemens
Institutions
- Vancouver Coastal Health (CA)
- University of British Columbia (CA)
- Fraser Health (CA)
- Richmond Hospital (CA)
- Surrey Memorial Hospital (CA)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/phar.4609
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15